The Management of Glioblastomas during the SARS-CoV-19 Pandemic: A Narrative Overview

Abstract

The SARS-CoV-2 pandemic and covid-19 diffusion are an international public health emergency. Patients with a history of cancer have a higher incidence of infection with severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) and higher risk of severe COVID-19–associated events. Glioblastoma is considered to be among the most aggressive cancers,in this direction the value of treatment must be balanced with risks of exposure to infection, inducing immunosuppression and survival benefit. the objective of this review is to present all international consensus recommendation for the management of patients with glioblastoma (GBM) to inform clinical practice. During this pandemic crisis, careful patient selection that balances the risks and benefits of treatment is paramount to optimize the care of patients with glioblastoma in this setting.